Patients with a common form of lung cancer — lung squamous cell carcinoma — have very few treatment options. That situation may soon change. A team of cancer biologists at Mayo Clinic in Florida is reporting in the Feb. 10 ...
Tags: Oncogene, lung cancer, PKCiota, SOX2
Ewing's Sarcoma is an aggressive pediatric cancer, most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has to date proven very difficult. ...
Tags: Ewing's Sarcoma, health, gene
Trovagene has adopted RainDance's RainDrop Digital PCR System for research and development, and for use in the Trovagene CLIA laboratory. In addition, Trovagene has successfully developed a cell-free DNA mutation assay leveraging the ...
Tags: Trovagene, Digital PCR System
Prometheus Laboratories is enrolling patients for Proclivity 01, a multi-center study of Proleukin (High Dose Interleukin-2 (HD IL-2)) combined with vemurafenib therapy in patients with Braf V600 mutation-positive metastatic melanoma (mM). ...
Tags: Prometheus, Proclivity 01 Study
Rheonix, a developer of molecular diagnostic platforms, will present data of its automated KRAS CARD molecular diagnostic assay. The KRAS CARD is designed to detect seven known somatic mutations of KRAS oncogene from either fresh or ...
Tags: Rheonix, KRAS CARD, diagnostic assay, KRAS assay
Cytocell, a developer of fluorescence in situ hybridization (FISH) probes for use in cancer analysis, has unveiled a ROS1 Breakapart FISH probe test for non-small-cell lung cancer (NSCLC). The molecular cytogenetic test, which utilizes ...
US-based Trovagene has developed a urine-based molecular diagnostic test to detect and monitor cancer mutations. The test quantitatively detects KRAS mutations in transrenal DNA,which may be originated from both normal and diseased cells. ...
Tags: Trovagene, molecular diagnostic test, cancer mutations, cancer monitoring